[1] |
ZHANG Yujia, MA Li.
Advances and controversies in emerging techniques of surgery on breast cancer
[J]. China Oncology, 2025, 35(4): 339-345.
|
[2] |
HU Wei, REN Xiaomeng, WANG Yang, ZHAO Peiqing, CAO Kai.
TIPE regulates glucometabolic reprogramming by modulating LDHA expression in triple-negative breast cancer
[J]. China Oncology, 2025, 35(4): 386-393.
|
[3] |
JIA Ruijie, SHI Zhiqiang, ZHANG Qi, LU Yongjin, ZHENG Junsheng, SUN Jing, BI Zhao, SUN Xiao, WANG Yongsheng, QIU Pengfei.
Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy
[J]. China Oncology, 2025, 35(4): 394-403.
|
[4] |
XUE Jialei, LI Jianwei, GONG Yue, LIU Guangyu, LIU Zhebin.
Predicting delayed diagnosis rate of intraoperative rapid frozen section pathological examination for early-stage breast cancer: a real-world retrospective study
[J]. China Oncology, 2025, 35(4): 404-411.
|
[5] |
WANG Zhiqing, LIU Xiyu, FAN Lei.
Advances and controversies in the adjuvant treatment of early breast cancer
[J]. China Oncology, 2025, 35(3): 255-262.
|
[6] |
WANG Xiaobo, WANG Tao.
Current status and future perspectives on consensus and controversies in advanced breast cancer for 2024
[J]. China Oncology, 2025, 35(3): 263-272.
|
[7] |
LI Bin, TAO Zhonghua, HU Xichun.
Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
[J]. China Oncology, 2025, 35(3): 273-282.
|
[8] |
WU Chunxiao, PANG Yi, GU Kai, YAN Jiaying, WANG Chunfang, XIANG Yongmei, SHI Yan.
Survival analysis of female breast cancer in Shanghai: a population-based study from 2002 to 2017
[J]. China Oncology, 2025, 35(3): 291-297.
|
[9] |
ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan.
Research status and prospects of treatment for malignant pleural mesothelioma
[J]. China Oncology, 2025, 35(3): 326-332.
|
[10] |
LU Yufeng, WANG Han, XIE Yifan, JIANG Yizhou, SHAO Zhimin.
Significant fundamental translational research on breast cancer in China: progress and prospects
[J]. China Oncology, 2025, 35(2): 143-153.
|
[11] |
LIN Jialin, WANG Wenna, XU Binghe.
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
[J]. China Oncology, 2025, 35(2): 154-166.
|
[12] |
YANG Xin, SHI Qianfeng, LIU Qiang.
Progress of important clinical research on breast cancer in China in 2024
[J]. China Oncology, 2025, 35(2): 167-175.
|
[13] |
LI Xing, PENG Ziqi, YU Xinmiao, JIN Feng.
Important research progress in clinical practice for early breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 176-185.
|
[14] |
WU Song, YUAN Yang, JIANG Zefei.
Important clinical studies that changed the clinical practice of advanced breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 186-194.
|
[15] |
ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei.
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
[J]. China Oncology, 2025, 35(2): 195-204.
|